EANS-Adhoc: - Marseille-Kliniken AG appoints new member to Management Board
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.
11.06.2010
Berlin, 11 June 2010. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) has appointed Dr. Thomas Klaue (52) to the Management Board effective 1 July 2010. He is undertaking the role of the Chief Financial Officer (CFO) and has also been appointed the Vice Chairman of the Management Board. This was resolved unanimously by the Supervisory Board in its meeting yesterday. The Management Board contract of Dr. Klaue has a term of three years.
Until April 2010, Dr. Klaue served as the CFO of MediGene AG, one of the leading German biotech companies based in Martinsried. Prior to that position, he worked in a number of executive roles at Infineon AG and Dasa.
Dr. Klaue is succeeding Claus Dobrowolski (53), who took over the role of interim CFO in April 2010. The Supervisory Board would like to thank Claus Dobrowolski for his valuable support.
End of ad hoc release
end of announcement euro adhoc
Further inquiry note:
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de
Marseille-Kliniken AG
Dr. Ute Buchheim
Friedrich-Ebert-Str. 65
33330 Gütersloh
Germany
Tel.: +49-(0)5241 / 90 39-35
Fax: +49-(0)5241 / 90 39-39
www.marseille-kliniken.com
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing